Aastrom Biosciences (NASDAQ:ASTM) has earned an average recommendation of “Hold” from the eight analysts that are covering the stock, AnalystRatingsNetwork reports. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $3.78. Aastrom Biosciences Inc (NASDAQ:ASTM) shares after opening at $3.78 moved to $4.12 on last trade day and at the end of the day closed at $3.97. Company twelve months price to cash ratio was 1.12. Aastrom Biosciences Inc (NASDAQ:ASTM) showed a positive weekly performance of 1.24%.
Concert Pharmaceuticals (NASDAQ:CNCE) firm got “buy” rating from Roth Capital and a $28.00 price target on the stock. Roth Capital’s target price would indicate a potential upside of 98.58% from the company’s current price. Concert Pharmaceuticals Inc(NASDAQ:CNCE) shares advanced -1.68% in last trading session and ended the day on $13.92. Concert Pharmaceuticals Inc(NASDAQ:CNCE) return on equity ratio is recorded as 33.70% and its return on assets is -64.60%.
Coronado Biosciences, Inc. (NASDAQ:CNDO) announced its financial results for the fourth quarter and year ended December 31, 2013.”Given the results of our TRUST-I Clinical Trial for Crohn’s Disease, we are evaluating clinical development plans for TSO,” said Dr. Lindsay A. Rosenwald, Coronado’s Chairman, President and CEO. “As part of our growth strategy, we plan to identify, evaluate and potentially in-license, acquire or invest in pharmaceutical and biotechnology products, technologies and/or companies. Coronado Biosciences Inc (NASDAQ:CNDO) shares moved up 4.43% in last trading session and was closed at $2.12, while trading in range of $2.02 – 2.19. Coronado Biosciences Inc (NASDAQ:CNDO) year to date (YTD) performance is -19.36%.
Durata Therapeutics Inc (NASDAQ:DRTX) is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. Durata Therapeutics Inc (NASDAQ:DRTX) weekly performance is 13.73%. On last trading day company shares ended up $16.65. Durata Therapeutics Inc (NASDAQ:DRTX) distance from 50-day simple moving average (SMA50) is 29.69%. Analysts mean target price for the company is $15.93.